Pfizer’s Phase 3 gene therapy trial for DMD
March 3rd, 2021
First participant dosed in Pfizer’s Phase 3 gene therapy trial for DMD
Pfizer has announced that the first participant has been dosed in the Phase 3 CIFFREO clinical trial. The CIFFREO study is testing the effectiveness and safety of the potential therapy drug PF-06939926 for the treatment of Duchenne muscular dystrophy (DMD). This is the first Phase 3 DMD gene therapy programme to begin dosing eligible participants. The first participant received the dose in Barcelona, Spain in December 2020. The CIFFREO trial aims to enrol 99 ambulatory boys, aged 4-7 at trial sites in 15 countries. More details will be added to the study website in due course. Read Pfizer’s press release for more information. Details on the CIFFREO study can be found here.
Categories: Information
